A Comparative Analysis of Naïve Exosomes and Enhanced Exosomes with a Focus on the Treatment Potential in Ovarian Disorders
Preprint
- 1 April 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Exosome-based therapy has emerged as a promising strategy for addressing diverse disorders, indicating the need for further exploration of the potential therapeutic effects of the exosome cargos. This study introduces "enhanced exosomes," a novel type of exosomes developed through a novel cell culture system. These specific exosomes may become potent therapeutic agents for treating ovarian disorders. In this study, we conducted a comparative analysis of the protein and miRNA cargo compositions of enhanced exosomes and naïve exosomes. Our findings revealed distinct cargo compositions in enhanced exosomes, featuring upregulated proteins such as EFEMP1, HTRA1, PAM, RSU1, and SDF4, suggesting their potential for treating ovarian disorders. MicroRNA profiling revealed that miR-1-3p, miR-103a-3p, miR-122-5p, miR-1271-5p, miR-133a-3p, miR-184, miR-203a-3p, and miR-206 are key players in regulating ovarian cancer and chemosensitivity by affecting cell cycle progression, cell proliferation, and cell development. We examined polycystic ovary syndrome and premature ovarian insufficiency and identified altered expression of various miRNAs, such as miR-106a-5p, miR-130b-5p, and miR-130b-3p, for diagnostic insights. This study highlights the potential of enhanced exosomes as new therapeutic agents for women's reproductive health, offering a detailed understanding of the impact of their cargo on ovarian disorders.Keywords
All Related Versions
This publication has 54 references indexed in Scilit:
- Attenuated miR-203b-3p is critical for ovarian cancer progression and aptamer/miR-203b-3p chimera can be explored as a therapeuticAdvances in Cancer Biology - Metastasis, 2022
- Exosomes – Spectacular role in reproductionBiomedicine & Pharmacotherapy, 2022
- Circ_0072995 Promotes Ovarian Cancer Progression Through Regulating miR-122-5p/SLC1A5 AxisBiochemical Genetics, 2021
- Salivary exosomes: properties, medical applications, and isolation methodsMolecular Biology Reports, 2020
- Modern Techniques for the Isolation of Extracellular Vesicles and VirusesJournal of Neuroimmune Pharmacology, 2019
- Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseasesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2019
- MiR‐122 inhibits epithelial mesenchymal transition by regulating P4HA1 in ovarian cancer cellsCell Biology International, 2018
- MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathwayBiomedicine & Pharmacotherapy, 2018
- miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptorTumor Biology, 2013
- HtrA1 sensitizes ovarian cancer cells to cisplatin‐induced cytotoxicity by targeting XIAP for degradationInternational Journal of Cancer, 2011